Gerald C. O'sullivan

Constitutive ERK1/2 Activation in Esophagogastric Rib Bone Marrow Micrometastatic Cells Is MEK-independent*

M. Kazanietz, J. K. Collins, G. O'sullivan, 2001, The Journal of Biological Chemistry.

Expression of Fas ligand by human gastric adenocarcinomas: a potential mechanism of immune escape in stomach cancer

C. Brady, F. Shanahan, J. K. Collins, 1999, Gut.

Correlation of probiotic Lactobacillus salivarius growth phase with its cell wall-associated proteome.

Richard J. Edwards, D. Fitzgerald, F. Shanahan, 2005, FEMS microbiology letters.

The Fas counterattack: cancer as a site of immune privilege.

F. Shanahan, J. K. Collins, M. Bennett, 1999, Immunology today.

The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma.

C. Brady, F. Shanahan, J. K. Collins, 1998, Journal of immunology.

Fas ligand upregulation is an early event in colonic carcinogenesis

F. Shanahan, J. K. Collins, M. Bennett, 2001, Journal of clinical pathology.

Probiotics: from myth to reality. Demonstration of functionality in animal models of disease and in human clinical trials

F. Shanahan, L. O’Mahony, E. Quigley, 1999, Antonie van Leeuwenhoek.

Resistance to Fas (APO-1/CD95)-mediated apoptosis and expression of Fas ligand in esophageal cancer: the Fas counterattack.

F. Shanahan, J. K. Collins, M. Bennett, 1999, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.